$ENTO
Entero Therapeutics Inc

2023 Q4 Form 10-Q Financial Statement

#000141057823002410 Filed on November 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.786M $2.420M
YoY Change 27.94% -16.68%
% of Gross Profit
Research & Development $1.307M $1.011M
YoY Change 1184.02% 27.81%
% of Gross Profit
Depreciation & Amortization $9.270K $7.300K
YoY Change 26.64% 0.0%
% of Gross Profit
Operating Expenses $4.094M $3.433M
YoY Change 79.57% -178.21%
Operating Profit -$3.433M
YoY Change -178.21%
Interest Expense -$6.830K $1.250K
YoY Change 355.33% 44.84%
% of Operating Profit
Other Income/Expense, Net -$500.00 -$1.021K
YoY Change -99.97% -156.69%
Pretax Income -$4.101M -$3.430M
YoY Change 2.88% -178.11%
Income Tax
% Of Pretax Income
Net Earnings -$4.178M -$3.434M
YoY Change 4.87% -178.2%
Net Earnings / Revenue
Basic Earnings Per Share -$0.46
Diluted Earnings Per Share -$5.35 -$0.46
COMMON SHARES
Basic Shares Outstanding 13.50M 7.152M
Diluted Shares Outstanding 7.566M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.712M $3.290M
YoY Change 172.34% 98.55%
Cash & Equivalents $3.700M $3.300M
Short-Term Investments
Other Short-Term Assets $1.244M $680.0K
YoY Change -36.4% -2.88%
Inventory
Prepaid Expenses $1.244M $684.3K
Receivables
Other Receivables
Total Short-Term Assets $4.956M $3.977M
YoY Change 45.23% 56.0%
LONG-TERM ASSETS
Property, Plant & Equipment $210.0K $21.88K
YoY Change 379.05% -57.22%
Goodwill $1.684M $1.684M
YoY Change 0.0% -1.78%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $32.77K $30.00K
YoY Change -17.37% -46.24%
Total Long-Term Assets $1.927M $1.951M
YoY Change -4.93% -6.95%
TOTAL ASSETS
Total Short-Term Assets $4.956M $3.977M
Total Long-Term Assets $1.927M $1.951M
Total Assets $6.883M $5.927M
YoY Change 26.54% 27.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $554.3K $579.3K
YoY Change -23.02% -83.83%
Accrued Expenses $892.4K $834.5K
YoY Change 178.72% 206.51%
Deferred Revenue
YoY Change
Short-Term Debt $612.8K $0.00
YoY Change 1.54%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.133M $2.482M
YoY Change 26.17% -62.92%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $147.0K $170.0K
YoY Change -31.35% -26.5%
Total Long-Term Liabilities $147.0K $170.0K
YoY Change -31.35% -26.5%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.133M $2.482M
Total Long-Term Liabilities $147.0K $170.0K
Total Liabilities $3.280M $2.648M
YoY Change 21.6% -61.76%
SHAREHOLDERS EQUITY
Retained Earnings -$184.3M -$180.2M
YoY Change 9.35% 9.54%
Common Stock $156.00 $1.346K
YoY Change 56.0% 482.68%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.603M $3.279M
YoY Change
Total Liabilities & Shareholders Equity $6.883M $5.927M
YoY Change 26.54% 27.59%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$4.178M -$3.434M
YoY Change 4.87% -178.2%
Depreciation, Depletion And Amortization $9.270K $7.300K
YoY Change 26.64% 0.0%
Cash From Operating Activities -$3.438M -$3.330M
YoY Change -38.53% -21.72%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$500.0K
YoY Change
Cash From Investing Activities -$500.0K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.357M 5.390M
YoY Change -21.13% 12.96%
NET CHANGE
Cash From Operating Activities -3.438M -3.330M
Cash From Investing Activities -500.0K
Cash From Financing Activities 4.357M 5.390M
Net Change In Cash 418.9K 2.060M
YoY Change -715.53% 297.94%
FREE CASH FLOW
Cash From Operating Activities -$3.438M -$3.330M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13463479
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
995003
dei Entity Registrant Name
EntityRegistrantName
First Wave BioPharma, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0001604191
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13463479
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
995003
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37853
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-4993860
dei Entity Address Address Line1
EntityAddressAddressLine1
777 Yamato Road, Suite 502
dei Entity Address City Or Town
EntityAddressCityOrTown
Boca Raton
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33431
dei City Area Code
CityAreaCode
561
dei Local Phone Number
LocalPhoneNumber
589-7020
dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
FWBI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
13499979
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3292327
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1362910
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
93014
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
684273
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1956831
CY2023Q3 us-gaap Assets Current
AssetsCurrent
3976600
CY2022Q4 us-gaap Assets Current
AssetsCurrent
3412755
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21884
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
43839
CY2023Q3 us-gaap Goodwill
Goodwill
1684182
CY2022Q4 us-gaap Goodwill
Goodwill
1684182
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
21521
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
21513
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
211832
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
259261
CY2023Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
11250
CY2022Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
18149
CY2023Q3 fwbi Assets Noncurrent Excluding Property Plant And Equipment Net
AssetsNoncurrentExcludingPropertyPlantAndEquipmentNet
1928785
CY2022Q4 fwbi Assets Noncurrent Excluding Property Plant And Equipment Net
AssetsNoncurrentExcludingPropertyPlantAndEquipmentNet
1983105
CY2023Q3 us-gaap Assets
Assets
5927269
CY2022Q4 us-gaap Assets
Assets
5439699
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
579291
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
720040
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
834540
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
320176
CY2023Q3 us-gaap Dividends Payable Current
DividendsPayableCurrent
992535
CY2022Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
761488
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
603494
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
65322
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
66151
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
10806
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
12138
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2482494
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2483487
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1801
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-16837
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-245258
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
165970
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
214060
CY2023Q3 us-gaap Liabilities
Liabilities
2648464
CY2022Q4 us-gaap Liabilities
Liabilities
2697547
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13463479
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
995003
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
1346
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
100
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
183505191
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
171275741
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-180227732
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-168533689
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
3278805
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
2742152
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5927269
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5439699
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1011055
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
791067
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3725833
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8674480
CY2022Q3 fwbi Research And Development Recovery Expenses Intellectual Property Acquired
ResearchAndDevelopmentRecoveryExpensesIntellectualPropertyAcquired
-8085045
fwbi Research And Development Recovery Expenses Intellectual Property Acquired
ResearchAndDevelopmentRecoveryExpensesIntellectualPropertyAcquired
-8085045
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2422082
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2904448
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7951373
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9808960
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
3433137
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
-4389530
us-gaap Operating Expenses
OperatingExpenses
11677206
us-gaap Operating Expenses
OperatingExpenses
10398395
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3433137
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
4389530
us-gaap Operating Income Loss
OperatingIncomeLoss
-11677206
us-gaap Operating Income Loss
OperatingIncomeLoss
-10398395
CY2023Q3 us-gaap Interest Expense
InterestExpense
1250
CY2022Q3 us-gaap Interest Expense
InterestExpense
863
us-gaap Interest Expense
InterestExpense
15415
us-gaap Interest Expense
InterestExpense
9686
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
229
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
2664
us-gaap Investment Income Interest
InvestmentIncomeInterest
2307
us-gaap Investment Income Interest
InvestmentIncomeInterest
3729
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3729
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-239301
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1021
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3434158
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
4391331
us-gaap Net Income Loss
NetIncomeLoss
-11694043
us-gaap Net Income Loss
NetIncomeLoss
-10643653
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-35235
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-230586
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3434158
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
4356096
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11694043
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10874239
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3434158
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
4391331
us-gaap Net Income Loss
NetIncomeLoss
-11694043
us-gaap Net Income Loss
NetIncomeLoss
-10643653
CY2022Q3 fwbi Deemed Dividend On Warrant Modification
DeemedDividendOnWarrantModification
47300
fwbi Deemed Dividend On Warrant Modification
DeemedDividendOnWarrantModification
47300
CY2023Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
49292
CY2022Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
110278
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
231047
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
298195
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3483450
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
4233753
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11925090
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10989148
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7566018
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
228773
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3763506
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
136113
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7566018
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
232248
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3763506
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
136113
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
18.51
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.17
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-80.74
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.46
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
18.23
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-80.74
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
881960
CY2023Q3 fwbi Stock And Warrants Issued During Period Value New Issues
StockAndWarrantsIssuedDuringPeriodValueNewIssues
1833927
CY2023Q3 fwbi Stock And Exercise Of Warrants Stock During Period Value Cash Net Of Offering Costs
StockAndExerciseOfWarrantsStockDuringPeriodValueCashNetOfOfferingCosts
3706771
CY2023Q3 fwbi Common Stock And Pre Funded Warrants Issued Upon Exercise Amount
CommonStockAndPreFundedWarrantsIssuedUponExerciseAmount
267
CY2023Q3 fwbi Deemed Dividend Of Series B Preferred Stock
DeemedDividendOfSeriesBPreferredStock
49292
CY2023Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
76000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
263330
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3434158
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
3278805
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-14189863
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7373355
CY2022Q3 fwbi Deemed Dividend Of Series B Preferred Stock
DeemedDividendOfSeriesBPreferredStock
110278
CY2022Q3 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
1
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
91641
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-35235
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
4391331
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-2280049
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
2742152
fwbi Common Stock And Pre Funded Warrants Issued Upon Exercise Amount
CommonStockAndPreFundedWarrantsIssuedUponExerciseAmount
657
fwbi Deemed Dividend Of Series B Preferred Stock
DeemedDividendOfSeriesBPreferredStock
231047
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
76000
us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
1
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
914350
us-gaap Net Income Loss
NetIncomeLoss
-11694043
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
3278805
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-7821550
fwbi Stock And Warrants Issued During Period Value New Issues
StockAndWarrantsIssuedDuringPeriodValueNewIssues
7971932
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7691222
fwbi Common Stock And Pre Funded Warrants Issued Upon Exercise Amount
CommonStockAndPreFundedWarrantsIssuedUponExerciseAmount
48013
fwbi Deemed Dividend Of Series B Preferred Stock
DeemedDividendOfSeriesBPreferredStock
298195
fwbi Warrant Modification
WarrantModification
47300
fwbi Deemed Dividend On Warrant Modifications
DeemedDividendOnWarrantModifications
47300
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
118990
us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
1
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
684778
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-230586
us-gaap Net Income Loss
NetIncomeLoss
-10643653
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-2280049
us-gaap Net Income Loss
NetIncomeLoss
-11694043
us-gaap Net Income Loss
NetIncomeLoss
-10643653
us-gaap Depreciation
Depreciation
21955
us-gaap Depreciation
Depreciation
21953
fwbi Change In Right Of Use Assets
ChangeInRightOfUseAssets
47429
fwbi Change In Right Of Use Assets
ChangeInRightOfUseAssets
61681
us-gaap Share Based Compensation
ShareBasedCompensation
914350
us-gaap Share Based Compensation
ShareBasedCompensation
684778
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
76000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
118990
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-93014
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
191984
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1272558
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-614809
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-48919
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-93438
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-6899
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-9714
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-140749
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
875257
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
514364
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-120985
fwbi Increase Decrease In Payables Related To Acquisition
IncreaseDecreaseInPayablesRelatedToAcquisition
-8085045
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-1332
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-3867
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8938474
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16751790
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
199000
fwbi Proceeds From Issuance Of Common Stock And Warrants Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts
5525010
fwbi Proceeds From Issuance Of Common Stock And Warrants Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts
7971932
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
5946383
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
48013
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
7691222
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
138684
fwbi Payment Made Related To Acquisition Agreement
PaymentMadeRelatedToAcquisitionAgreement
4914955
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
603494
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
641236
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10867899
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10215292
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1929425
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-6536498
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-33668
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1384423
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8248684
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3313848
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1678518
us-gaap Interest Paid Net
InterestPaidNet
15414
us-gaap Interest Paid Net
InterestPaidNet
8824
fwbi Deemed Dividend On Warrant Modifications
DeemedDividendOnWarrantModifications
47300
CY2023Q3 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
231047
CY2022Q3 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
298195
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3300000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-180200000
CY2023Q3 fwbi Working Capital Deficiency
WorkingCapitalDeficiency
1500000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited condensed consolidated financial statements are prepared in conformity with GAAP and include certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements (including goodwill), and the reported amounts of revenue and expense during the reporting period, including contingencies. Accordingly, actual results may differ from those estimates.</p>
CY2023Q1 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
7
CY2023Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
20000.00
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
20000.00
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist of cash. The Company primarily maintains its cash balances with financial institutions in federally insured accounts in the U.S. The Company may from time to time have cash in banks in excess of FDIC insurance limits. At September 30, 2023 the Company had approximately $3.2 million in one account in the U.S. which was in excess of these limits. The Company has not experienced any losses to date resulting from this practice. The Company mitigates its risk by maintaining the majority of its cash and equivalents with high quality financial institutions.</p>
CY2023Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
3200000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2022Q4 us-gaap Notes Payable Fair Value Disclosure
NotesPayableFairValueDisclosure
603494
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
87818
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
87818
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
65934
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
43979
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21884
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
43839
CY2022Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7300
CY2023Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7300
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
22000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
22000
CY2021Q4 us-gaap Goodwill
Goodwill
1911705
CY2022 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-227523
CY2022Q4 us-gaap Goodwill
Goodwill
1684182
us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
0
CY2023Q3 us-gaap Goodwill
Goodwill
1684182
CY2023Q3 fwbi Accrued License Fee
AccruedLicenseFee
500000
CY2023Q3 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
244215
CY2022Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
309867
CY2023Q3 fwbi Consulting Fees
ConsultingFees
82974
CY2022Q4 fwbi Consulting Fees
ConsultingFees
4969
CY2023Q3 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
7351
CY2022Q4 fwbi Clinical Trials
ClinicalTrials
5340
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
834540
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
320176
CY2023Q3 fwbi Note Payables
NotePayables
0
CY2022Q4 fwbi Note Payables
NotePayables
603000
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
7
CY2022Q3 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
30
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13463479
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
995003
CY2022 fwbi Deemed Dividend On Warrant Modification
DeemedDividendOnWarrantModification
-47000.000
CY2022Q1 fwbi Stocks Issued During Period Shares Common Stock Pre Funded Warrants And Warrants For Cash Net Of Offering Costs
StocksIssuedDuringPeriodSharesCommonStockPreFundedWarrantsAndWarrantsForCashNetOfOfferingCosts
7857
CY2022Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1
fwbi Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P4Y25D
CY2022Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
288.75
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8000000.0
CY2022Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
264.60
CY2022Q1 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
fwbi Stock Cancelled During Period Shares Acquisitions
StockCancelledDuringPeriodSharesAcquisitions
2967
us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
1
CY2022Q3 fwbi Stock Cancelled During Period Shares Acquisitions
StockCancelledDuringPeriodSharesAcquisitions
12
CY2022Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
30
fwbi Stock Cancelled During Period Shares Acquisitions
StockCancelledDuringPeriodSharesAcquisitions
12
us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
30
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2179798
CY2022Q4 fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Outstanding And Exercisable
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsOutstandingAndExercisable
19.16
CY2022 fwbi Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P5Y6M
fwbi Class Of Warrant Or Right Granted
ClassOfWarrantOrRightGranted
27398790
fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Granted
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted
0.73
fwbi Class Of Warrant Or Right Issued Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightIssuedWeightedAverageRemainingContractualTerm
P4Y7M2D
fwbi Class Of Warrant Or Right Expired
ClassOfWarrantOrRightExpired
116
fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Expired
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired
-773.79
fwbi Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
11605861
fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercised
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised
-0.96
fwbi Class Of Warrant Or Right Exercised Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightExercisedWeightedAverageRemainingContractualTerm
P4Y8M19D
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
17972611
CY2023Q3 fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Outstanding And Exercisable
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsOutstandingAndExercisable
2.38
fwbi Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P4Y10M20D
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
26089
CY2021Q4 fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Outstanding And Exercisable
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsOutstandingAndExercisable
1992.90
CY2021 fwbi Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P3Y11M12D
fwbi Class Of Warrant Or Right Granted
ClassOfWarrantOrRightGranted
66317
fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Granted
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted
142.52
fwbi Class Of Warrant Or Right Issued Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightIssuedWeightedAverageRemainingContractualTerm
P4Y5M26D
fwbi Class Of Warrant Or Right Expired
ClassOfWarrantOrRightExpired
596
fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Expired
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired
-7880.46
fwbi Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
23086
fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercised
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised
-2.10
fwbi Class Of Warrant Or Right Exercised Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightExercisedWeightedAverageRemainingContractualTerm
P4Y5M1D
CY2022Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
68724
CY2022Q3 fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Outstanding And Exercisable
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsOutstandingAndExercisable
631.33
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
5000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3266
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
263330
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
91641
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
914350
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
684778
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
600000
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
900000
CY2023Q3 fwbi Number Of Real Property Operating Leases
NumberOfRealPropertyOperatingLeases
1
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
42000
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
36000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
18.51
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.17
us-gaap Operating Lease Expense
OperatingLeaseExpense
114000
us-gaap Operating Lease Expense
OperatingLeaseExpense
115000
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y10M24D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0700
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
42360
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
86202
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
88788
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
60593
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
277943
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
46651
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
231292
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3483450
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
4233753
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11925090
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10989148
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7566018
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
228773
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3763506
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
136113
CY2022Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
3475
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7566018
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
232248
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3763506
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
136113
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-80.74
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.46
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
18.23
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-80.74
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18057807
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
76355
us-gaap Defined Contribution Plan Employers Matching Contribution Annual Vesting Percentage
DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage
0.06
CY2022Q3 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
21000
CY2023Q3 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
21000
us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
68000
us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
97000

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001410578-23-002410-index-headers.html Edgar Link pending
0001410578-23-002410-index.html Edgar Link pending
0001410578-23-002410.txt Edgar Link pending
0001410578-23-002410-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
fwbi-20230930.xsd Edgar Link pending
fwbi-20230930x10q.htm Edgar Link pending
fwbi-20230930xex31d1.htm Edgar Link pending
fwbi-20230930xex31d2.htm Edgar Link pending
fwbi-20230930xex32d1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
fwbi-20230930_cal.xml Edgar Link unprocessable
fwbi-20230930_def.xml Edgar Link unprocessable
fwbi-20230930_lab.xml Edgar Link unprocessable
fwbi-20230930_pre.xml Edgar Link unprocessable
fwbi-20230930x10q_htm.xml Edgar Link completed
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending